Executive Profile: Pfizer's Geno Germano On Impatience, Innovation And The Influence Of Culture
This article was originally published in Scrip
Executive Summary
Geno Germano is group president of Pfizer's Global Innovative Pharma Business, the unit focused on development, registration and commercialization of novel medicines. He is co-chair of the portfolio strategy and investment committee, which aims to maximize the return on R&D investment across the Pfizer portfolio. Germano also manages Pfizer's global health and value function, which works to demonstrate the value of innovation and supports access to Pfizer's medicines. In the latest edition of Scrip's executive profile series, he tells Sukaina Virji of his childhood propensity for hard work, how youthful impatience led him to a successful career in the pharmaceutical industry, and the influence of culture on effectiveness.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.